Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genky Drug Stores CoTSE:9267 +3.24%82 Return-on-Tangible-Equity is 11.02% as of Mar. 2026, which is 21% below its 10-year median of 14.00. GuruFocus rates TSE:9267 with a GF Score™ of 82/100 and a GF Value™ of 円3,791.60 (Fairly Valued). The stock has 2 warning signs investors should review. Among 585 Healthcare Providers & Services companies, Genky Drug Stores Co ranks better than 58.46% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Genky Drug Stores Co's annualized net income for the quarter that ended in Mar. 2026 was 円6,404 Mil. Genky Drug Stores Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円58,100 Mil. Therefore, Genky Drug Stores Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.02%.
The historical rank and industry rank for Genky Drug Stores Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:9267'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.52 Med: 14 Max: 20.88
Current: 13.79
During the past 13 years, Genky Drug Stores Co's highest Return-on-Tangible-Equity was 20.88%. The lowest was 10.52%. And the median was 14.00%.
TSE:9267's Return-on-Tangible-Equity is ranked better than 58.46% of 585
companies
in the Healthcare Providers & Services industry
Industry Median: 10.76
vs TSE:9267: 13.79
Genky Drug Stores Co (TSE:9267) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Genky Drug Stores Co Return-on-Tangible-Equity Related Terms
Genky Drug Stores Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Genky Drug Stores Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genky Drug Stores Co Return-on-Tangible-Equity Chart
Genky Drug Stores Co Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Genky Drug Stores Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genky Drug Stores Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Genky Drug Stores Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Genky Drug Stores Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.02% mean?
Genky Drug Stores Co (TSE:9267) has a Return-on-Tangible-Equity of 11.02% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genky Drug Stores Co and its competitors. This is 21% below median its historical median of 14.00. Over the past decade, Genky Drug Stores Co's Return-on-Tangible-Equity has ranged from 10.52 to 20.88. According to the industry distribution chart, Genky Drug Stores Co ranks #243 out of 585 companies in the Healthcare Providers & Services industry, placing it in the top 41.5%.
Is Genky Drug Stores Co's Return-on-Tangible-Equity too high?
Genky Drug Stores Co's current Return-on-Tangible-Equity of 11.02% is 21% below median its 10-year median of 14.00. Over the past 10 years, this metric has ranged from a low of 10.52 to a high of 20.88. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.76. Genky Drug Stores Co's value of 11.02% is 2.4% above this industry median. Based on the distribution chart, Genky Drug Stores Co ranks #243 out of 585 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Genky Drug Stores Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genky Drug Stores Co's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Genky Drug Stores Co ranks #243 out of 585 companies for Return-on-Tangible-Equity. This puts Genky Drug Stores Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.76. Genky Drug Stores Co's value of 11.02% is 2.4% above this benchmark. Historically, Genky Drug Stores Co's own Return-on-Tangible-Equity has ranged from 10.52 to 20.88 over the past decade. While the company's 10-year median is 14.00 vs. the industry median of 10.76, Genky Drug Stores Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.76, based on 585 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genky Drug Stores Co's current Return-on-Tangible-Equity of 11.02% is 2.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genky Drug Stores Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genky Drug Stores Co's current Return-on-Tangible-Equity is 11.02%, which is 21% below median its own 10-year median of 14.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genky Drug Stores Co stock overvalued right now?
Based on GuruFocus' analysis, Genky Drug Stores Co (TSE:9267) is currently considered Fairly Valued. The stock's GF Value™ is 円3,791.60, compared to a current price of 円3,665.00 — trading 3.3% below its estimated fair value. The current Return-on-Tangible-Equity is 11.02%, which is 21% below median its 10-year median of 14.00 and 2.4% above the Healthcare Providers & Services industry median of 10.76. Genky Drug Stores Co's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Genky Drug Stores Co (TSE:9267), the current Return-on-Tangible-Equity is 11.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genky Drug Stores Co (TSE:9267) Overvalued in 2026?
Based on GuruFocus' analysis, Genky Drug Stores Co stock appears to be undervalued.
The current stock price of 円3,665.00 is trading 3.3% below its estimated GF Value™ of 円3,791.60.
GuruFocus considers Genky Drug Stores Co to be Fairly Valued.
Key valuation signals for TSE:9267:
Return-on-Tangible-Equity: 11.02% (21% below median its 10-year median of 14.00)
GF Value™: 円3,791.60 vs. price of 円3,665.00 (3.3% below fair value)
Industry Position: 2.4% above the Healthcare Providers & Services median (#243 of 585)
No single metric tells the full story. See the TSE:9267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9267 has been successfully added to your 
